Viron Therapeutics is a clinical stage biopharmaceutical company developing a completely new class of anti-inflammatory therapeutics to treat and prevent human inflammatory disorders.  Viron's novel approach to drug development is based on the use of viral proteins as a source of therapeutic products.   By harnessing the evolutionary power of viruses to withstand the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy.  The Company's lead compound, VT-111, is currently in a Phase II clinical trial for the treatment of vascular inflammation in patients with Acute Coronary Syndromes and will soon submit an IND for its second indication, the prevention of chronic organ rejection in transplant patients. Viron's pipeline of additional compounds in preclinical development, combined with a robust discovery program, strongly positions the Company to be a leader in the discovery and commercialization of bio-therapeutics to treat inflammatory based diseases.